Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Three years after beginning construction in southwestern Wake County, the pharmaceutical company Amgen celebrated the ...

Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...